In this issue of Rheumatic Disease Clinics, guest editors Drs. Alexa Simon Meara and David Liew bring their considerable expertise to the topic of Rheumatic Immune-Related Adverse Events. Immune checkpoint inhibitors sometimes cause rheumatic-disease-like symptoms, or rheumatic immune-related adverse events (irAEs). In this issue, top experts discuss the utility of laboratory investigations for rheumatic irAEs; the future of biomarkers in rheumatic irAEs; integrating rheumatic irAE research and care into an oncological milieu; patient voices in rheumatic irAE care and research; polymyalgia rheumatica irAEs; inflammatory arthritis irAEs: current approaches to management; and more.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xiv 7. Foreword - p. xv 8. Preface - p. xvii 9. Pre-existing Autoimmune Diseases and Immune Checkpoint Inhibitors for Cancer Treatment: Considerations About Initiation, Flares, Immune-Related Adverse Events, and Cancer Progression - p. 147 10. Mimickers of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis - p. 161 11. The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events - p. 181 12. The Current and Future of Biomarkers of Immune Related Adverse Events - p. 201 13. Immunotherapy Toxicity Management in Clinical Practice: Building the Clinical Infrastructure for Immune-related Adverse Event Evaluation and Care - p. 229 14. Patient Voices in Rheumatic Immune-related Adverse Events - p. 241 15. Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica - p. 255 16. Immune Checkpoint Inhibitor-induced Inflammatory Arthritis: Current Approaches to Management - p. 269 17. Immune Checkpoint Inhibitor-induced Myositis - p. 281 18. Immune Checkpoint Inhibitor-induced Sicca Syndrome - p. 291 19. De novo Connective Tissue Disorders as Immune-related Adverse Events - p. 301 20. Imaging in Rheumatic Immune-related Adverse Events - p. 313 21. The Need for Classification Criteria of Immune Checkpoint Inhibitor-induced inflammatory Arthritis: A Scoping Review - p. 325 22. Impact of Non-steroidal Anti-inflammatory Drugs, Glucocorticoids, and Disease-Modifying Anti-Rheumatic Drugs on Cancer Response to Immune Checkpoint Inhibitor Therapy - p. 337
In this issue of Rheumatic Disease Clinics, guest editors Drs. Alexa Simon Meara and David Liew bring their considerable expertise to the topic of Rheumatic Immune-Related Adverse Events. Immune checkpoint inhibitors sometimes cause rheumatic-disease-like symptoms, or rheumatic immune-related adverse events (irAEs). In this issue, top experts discuss the utility of laboratory investigations for rheumatic irAEs; the future of biomarkers in rheumatic irAEs; integrating rheumatic irAE research and care into an oncological milieu; patient voices in rheumatic irAE care and research; polymyalgia rheumatica irAEs; inflammatory arthritis irAEs: current approaches to management; and more.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xiv 7. Foreword - p. xv 8. Preface - p. xvii 9. Pre-existing Autoimmune Diseases and Immune Checkpoint Inhibitors for Cancer Treatment: Considerations About Initiation, Flares, Immune-Related Adverse Events, and Cancer Progression - p. 147 10. Mimickers of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis - p. 161 11. The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events - p. 181 12. The Current and Future of Biomarkers of Immune Related Adverse Events - p. 201 13. Immunotherapy Toxicity Management in Clinical Practice: Building the Clinical Infrastructure for Immune-related Adverse Event Evaluation and Care - p. 229 14. Patient Voices in Rheumatic Immune-related Adverse Events - p. 241 15. Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica - p. 255 16. Immune Checkpoint Inhibitor-induced Inflammatory Arthritis: Current Approaches to Management - p. 269 17. Immune Checkpoint Inhibitor-induced Myositis - p. 281 18. Immune Checkpoint Inhibitor-induced Sicca Syndrome - p. 291 19. De novo Connective Tissue Disorders as Immune-related Adverse Events - p. 301 20. Imaging in Rheumatic Immune-related Adverse Events - p. 313 21. The Need for Classification Criteria of Immune Checkpoint Inhibitor-induced inflammatory Arthritis: A Scoping Review - p. 325 22. Impact of Non-steroidal Anti-inflammatory Drugs, Glucocorticoids, and Disease-Modifying Anti-Rheumatic Drugs on Cancer Response to Immune Checkpoint Inhibitor Therapy - p. 337
